Ocrelizumab not recommended in France for patients with primary progressive multiple sclerosis while recommended in England: a review comparing the assessment by HAS and NICE
Expert opinion on biological therapy, vol. 21, no. 6, pp. 741-747
Contributions to Journals: Review articles
- Digital Object Identifier
- https://doi.org/10.1080/14712598.2021.1865305
- Open Access
- http://aura.abdn.ac.uk/bitstream/2164/17774/1/Armoiry_etal_EOBT_Ocrelizumab_AAM.pdf
- Additional Links
- View publication in Scopus